Structure Therapeutics Inc.
GPCRDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GPCR's past catalysts played out
GSBR-1290
Overweight or Obesity
Aleniglipron
Obesity, Overweight, or Chronic Weight Management
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GSBR-1290 | Phase 2 | Overweight or Obesity | - | - |
Aleniglipron | Phase 2 | Obesity, Overweight, or Chronic Weight Management | - | - |
Frequently asked questions
What is in Structure Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Structure Therapeutics Inc.'s (GPCR) pipeline across Phase 2. Its lead program is GSBR-1290 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Structure Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Structure Therapeutics Inc. (GPCR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GPCR biotech catalysts?→
Add GPCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Structure Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.